We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Lateral Flow Assays Market Driven by Increasing Demand for Rapid and Portable Diagnostic Solutions

By LabMedica International staff writers
Posted on 28 Jun 2023
Print article
Image: The global lateral flow assays market is expected to touch USD 14 billion in 2030 (Photo courtesy of Freepik)
Image: The global lateral flow assays market is expected to touch USD 14 billion in 2030 (Photo courtesy of Freepik)

Lateral flow assays, also known as lateral flow immunoassays or lateral flow tests, are diagnostic tools created for fast, point-of-care detection of various substances. They are widely used in applications such as pregnancy tests, diagnosis of infectious diseases, drug screening, food safety verification, and veterinary diagnostics. Due to their user-friendly nature, swift results, minimal equipment needs, and cost-effectiveness, these tests can be conveniently used in diverse environments like hospitals, clinics, homes, and remote areas. Over the years, the lateral flow assays market has seen consistent growth, primarily driven by the global increase in demand for rapid, portable diagnostic solutions, irrespective of the development status of the region.

The global lateral flow assays market was valued at almost USD 10 billion in 2022 and is expected to register a CAGR of 4.25% during the forecast period 2023-2030 to reach close to USD 14 billion in 2030. These are the latest findings of ResearchAndMarkets.com (Dublin, Ireland), a leading source for international market research reports and market data.

Based on technique, the sandwich assays segment dominates the lateral flow assay kits & reagents market with the largest share. Due to their high sensitivity and specificity for larger analyses, sandwich assays are extensively used in clinical testing. By type, the lateral flow readers segment is expected to witness the highest growth during the forecast period. Lateral flow readers offer quantitative analysis of lateral flow strips across various test formats like sandwich, competitive, and reverse-competitive. They measure the intensity of the test line to estimate the number of analytes present in samples, thus providing fully quantitative assay results.

Geographically, North America leads the global lateral flow assay market due to increasing demand for home healthcare services, the rising prevalence of multiple chronic conditions, early adoption of test procedures, and the presence of numerous key players in the region. Europe is the world’s second-largest market for lateral flow assays due to the rising prevalence of infectious diseases leading to a surge in demand for diagnostic tests, including lateral flow assays. Furthermore, with a noticeable increase in drug and alcohol consumption in Europe, the demand for lateral flow assays for monitoring and screening applications has increased in the region.

Related Links:
ResearchAndMarkets.com

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.